A new drug, PP353, developed by Persica Pharmaceuticals, aims to alleviate lower back pain by targeting infections rather than symptoms. Tested in a trial involving 44 patients, the results showed significant benefits for 60% of participants, reducing pain and disability. PP353, composed of an antibiotic (linezolid), a contrast agent (iohexol), and a thermosensitive gel, is administered via two injections four days apart. Doctors believe the drug could transform treatment for the 25% of chronic lower back pain cases caused by infections. Further trials are needed before it becomes widely available. Although some healthcare professionals are skeptical due to the limited trial size, market research suggests millions worldwide could benefit from this approach to back pain management.